4/A: Artivion CEO James P. Mackin Amends SEC Filing to Correct Share Reporting After LTIP Vesting
SEC Form 4/A (Amendment)
Artivion's CEO, James P. Mackin, files an amendment to a previous SEC Form 4 to correct the number of shares beneficially owned following the vesting of performance stock units and subsequent sell-to-cover transactions.
Summary
- James P. Mackin, CEO of Artivion, Inc., filed an amended Form 4 with the SEC on March 14, 2024, to correct a previous filing from March 7, 2024.
- The amendment addresses an administrative error in reporting the number of shares sold in sell-to-cover transactions on February 26, 2024.
- On March 1, 2024, Mackin acquired 28,618 shares of common stock related to LTIP performance stock units.
- On March 5, 2024, Mackin sold 13,996 shares at $18.7223 per share to cover tax withholding obligations upon the vesting of performance stock units.
- Following these transactions, Mackin beneficially owns 706,038 shares of Artivion common stock.
Sentiment
Score: 6
Explanation: The sentiment is neutral. While there's a correction of an error, it doesn't necessarily indicate a positive or negative outlook for the company. The transactions are related to compensation and tax obligations, which are routine.
Negatives
- The amended filing indicates a previous administrative error in reporting share transactions, which could raise concerns about internal controls.
Risks
- Potential for increased scrutiny from regulators due to the need for an amended filing.
- Negative market reaction if investors perceive the error as indicative of broader issues with financial reporting.
Management Comments
- The sale was to satisfy tax withholding obligations to be funded by a sell to cover transaction and does not represent a discretionary transaction.
Industry Context
Executive stock transactions are a normal part of corporate governance, but errors in reporting can draw unwanted attention. Investors often monitor these filings for insights into management's perspective on the company's value.
Comparison to Industry Standards
- Comparing Artivion's executive compensation and stock ownership with similar medical device companies like Medtronic or Boston Scientific could provide context.
- Analyzing the frequency and nature of SEC filings by executives at these companies can help assess whether Artivion's situation is typical or unusual.
- Benchmarking Artivion's LTIP structure against industry standards can reveal if the vesting schedules and performance metrics are aligned with best practices.
Stakeholder Impact
- The correction of the filing ensures transparency for shareholders.
- The stock sale to cover tax obligations has a minor impact on the overall share supply.
Key Dates
| Date | Description |
|---|---|
| 02/26/2024 | Date of the sell to cover transactions where an administrative error occurred in reporting the number of shares sold. |
| 03/01/2024 | Date of acquisition of 28,618 shares of common stock related to LTIP performance stock units. |
| 03/05/2024 | Date of sale of 13,996 shares at $18.7223 per share to cover tax withholding obligations. |
| 03/07/2024 | Date of original Form 4 filing that was subsequently amended. |
| 03/14/2024 | Date of the amended Form 4/A filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.